COMPARATIVE EFFECTIVENESS AND CARDIOVASCULAR SAFETY OF ABALOPARATIDE AND TERIPARATIDE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN REAL WORLD USE

被引：0
|
作者：
McCloskey, E. V. [1 ]
机构：
[1] Univ Sheffield, Mellanby Ctr Musculoskeletal Res, Ctr Integrated Res Musculoskeletal Ageing, Dept Oncol & Metab,Acad Unit Bone Metab, Sheffield, S Yorkshire, England
来源：
AGING CLINICAL AND EXPERIMENTAL RESEARCH | 2023年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
SY10
引用
收藏
页码：S581 / S582
页数：2
相关论文
共 50 条
  • [1] COMPARATIVE EFFECTIVENESS AND SAFETY OF ABALOPARATIDE AND TERIPARATIDE IN THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Ren, Y.
    Vyas, A.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S33 - S33
  • [2] The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis
    Hartz, Martin C.
    Johannessen, Fabian B.
    Harslof, Torben
    Langdahl, Bente L.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,
  • [3] Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study
    Cosman, F.
    Cooper, C.
    Wang, Y.
    Mitlak, B.
    Varughese, S.
    Williams, S. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2022, 33 (08) : 1703 - 1714
  • [4] Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study
    F. Cosman
    C. Cooper
    Y. Wang
    B. Mitlak
    S. Varughese
    S. A. Williams
    [J]. Osteoporosis International, 2022, 33 : 1703 - 1714
  • [5] COMPARATIVE EFFECTIVENESS AND CARDIOVASCULAR SAFETY OF ABALOPARATIDE AND TERIPARATIDE IN POST-MENOPAUSAL WOMEN NEW TO ANABOLIC THERAPY: A US REAL-WORLD DATABASE STUDY
    Cosman, F.
    Cooper, C.
    Wang, Y.
    Mitlak, B.
    Varughese, S.
    Williams, S.
    [J]. AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (SUPPL 1) : S40 - S40
  • [6] Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis
    Ebina, Kosuke
    Etani, Yuki
    Noguchi, Takaaki
    Nakata, Ken
    Okada, Seiji
    [J]. JOURNAL OF BONE AND MINERAL METABOLISM, 2024,
  • [7] COST-EFFECTIVENESS OF ABALOPARATIDE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Hiligsmann, M.
    Williams, S. A.
    Fitzpatrick, L. A.
    Reginster, J. -Y.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S50 - S51
  • [8] COST-EFFECTIVENESS OF ABALOPARATIDE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Hansson-Hedblom, A.
    Geale, K.
    Borgstrom, F.
    Johansson, H.
    Fitzpatrick, L.
    Kanis, J. A.
    [J]. VALUE IN HEALTH, 2018, 21 : S197 - S197
  • [9] Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial
    Cosman, Felicia
    Peterson, Linda R.
    Towler, Dwight A.
    Mitlak, Bruce
    Wang, Yamei
    Cummings, Steven R.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (11): : 3384 - 3395
  • [10] Effect of Abaloparatide and Teriparatide on marrow adipose tissue in postmenopausal osteoporosis
    Veldhuis-Vlug, Annegreet G.
    Van 'T Hof, Rob J.
    Baron, Roland
    Black, Dennis M.
    Rosen, Clifford J.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 : 347 - 348
12345